[Assessment of a transfusion emergent risk: the case of HEV]

Transfus Clin Biol. 2014 Nov;21(4-5):162-6. doi: 10.1016/j.tracli.2014.07.004. Epub 2014 Sep 27.
[Article in French]

Abstract

Background: The risk assessment for blood transfusion is an essential step that must precede any screening strategy of a pathogen transmitted by transfusion. After several cases of HEV transmission by transfusion in France, a risk assessment for this virus was performed.

Methods: We used a method based on the prevalence of HEV-RNA in plasmas collected for the preparation of SD-plasma. To estimate the rate of HEV-RNA positive among all blood donations, data on SD-plasma were adjusted on the following HEV risk factors: gender, age group and region of residence. We assumed that HEV risk factors were the same in plasma donors and whole blood donors.

Results: Among 57,101 plasma donations tested for HEV-RNA in 2013, 24 were positive (crude rate of 4.2 per 10,000 donations). After adjustment, the total number of HEV-RNA positive blood donations was estimated at 788, accounting for a rate of 2.65 per 10,000 donations (95% CI: 1.6-3.7) or 1 in 3800 donations (1 in 6,200-1 in 2,700). This rate was 12 times higher in men than in women, increased with age, and varied according to region of residence.

Conclusion: The risk of blood donation contamination by HEV has been estimated to be 1 in 3800 donations in 2013. An essential input is still missing to assess now the risk in recipients: the minimum infectious dose. Furthermore, the risk in recipients has to be analyzed according to characteristics of transfused patients: presence of anti-HEV immunity, existence of chronic liver disease or immunodeficiency.

Keywords: Blood transfusion; HEV; Risk assessment; Transfusion sanguine; VHE; Évaluation de risque.

MeSH terms

  • Blood Donors
  • Blood Safety / standards*
  • Communicable Diseases, Emerging / blood
  • Communicable Diseases, Emerging / diagnosis
  • Communicable Diseases, Emerging / epidemiology*
  • Communicable Diseases, Emerging / prevention & control
  • Communicable Diseases, Emerging / transmission
  • Donor Selection*
  • Europe / epidemiology
  • Female
  • France / epidemiology
  • Global Health
  • Hepatitis E / blood
  • Hepatitis E / diagnosis
  • Hepatitis E / epidemiology*
  • Hepatitis E / prevention & control
  • Hepatitis E / transmission
  • Hepatitis E virus / genetics
  • Hepatitis E virus / isolation & purification
  • Humans
  • Male
  • Plasma / virology
  • RNA, Viral / blood*
  • Risk
  • Risk Assessment / methods*
  • Transfusion Reaction*
  • Viremia / diagnosis
  • Viremia / epidemiology
  • Viremia / transmission

Substances

  • RNA, Viral